CA3147891A1 - Methods of treating congenital adrenal hyperplasia - Google Patents
Methods of treating congenital adrenal hyperplasia Download PDFInfo
- Publication number
- CA3147891A1 CA3147891A1 CA3147891A CA3147891A CA3147891A1 CA 3147891 A1 CA3147891 A1 CA 3147891A1 CA 3147891 A CA3147891 A CA 3147891A CA 3147891 A CA3147891 A CA 3147891A CA 3147891 A1 CA3147891 A1 CA 3147891A1
- Authority
- CA
- Canada
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- subject
- level
- upper limit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962876176P | 2019-07-19 | 2019-07-19 | |
| US62/876,176 | 2019-07-19 | ||
| US202063047822P | 2020-07-02 | 2020-07-02 | |
| US63/047,822 | 2020-07-02 | ||
| PCT/US2020/042820 WO2021016208A1 (en) | 2019-07-19 | 2020-07-20 | Methods of treating congenital adrenal hyperplasia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3147891A1 true CA3147891A1 (en) | 2021-01-28 |
Family
ID=74193935
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3147891A Pending CA3147891A1 (en) | 2019-07-19 | 2020-07-20 | Methods of treating congenital adrenal hyperplasia |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20220133742A1 (https=) |
| EP (1) | EP3986416A4 (https=) |
| JP (1) | JP2022541550A (https=) |
| KR (1) | KR20220052927A (https=) |
| CN (1) | CN114423436A (https=) |
| AU (1) | AU2020318970B2 (https=) |
| BR (1) | BR112022000956A2 (https=) |
| CA (1) | CA3147891A1 (https=) |
| MX (1) | MX2022000812A (https=) |
| TW (1) | TW202116324A (https=) |
| WO (1) | WO2021016208A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS65839B1 (sr) | 2014-01-21 | 2024-09-30 | Neurocrine Biosciences Inc | Crf1 receptor antagonisti za tretman kongenitalne adrenalne hiperplazije |
| WO2019036503A1 (en) | 2017-08-14 | 2019-02-21 | Spruce Biosciences, Inc. | CORTICOTROPIN RELEASE FACTOR RECEPTOR ANTAGONISTS |
| EP4643950A3 (en) | 2018-04-27 | 2026-01-14 | Spruce Biosciences, Inc. | Methods for treating testicular and ovarian adrenal rest tumors |
| US20220023266A1 (en) | 2018-12-07 | 2022-01-27 | Neurocrine Biosciences, Inc. | Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia |
| JP7623365B2 (ja) | 2019-09-27 | 2025-01-28 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | Ｃｒｆ受容体アンタゴニストおよび使用方法 |
| KR20240023691A (ko) * | 2020-08-12 | 2024-02-22 | 스프루스 바이오사이언시스 인코포레이티드 | 다낭성 난소 증후군을 치료하기 위한 방법 및 조성물 |
| US20240024330A1 (en) * | 2020-08-26 | 2024-01-25 | Neurocrine Biosciences, Inc. | Crf receptor antagonists and methods of use |
| MD20210019A2 (ro) | 2021-04-12 | 2022-10-31 | Максим МАСЮТИН | Metodă de tratament a hiperplaziei suprarenale congenitale, cauzate de deficit de 21-hidroxilază cu debut tardiv prin regimul de glucocorticoizi adaptat individual |
| JP2024539907A (ja) * | 2021-11-19 | 2024-10-31 | スプルース バイオサイエンシーズ，インク． | チルダセルフォントの結晶性組成物ならびにその使用方法および調製方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050085479A1 (en) * | 2003-08-27 | 2005-04-21 | Pharmacia Corporation | Mediated central nervous system compositions of a cyclooxygenase-2 selective inhibitor and a corticotropin releasing factor antagonist for the treatment of ischemic disorders or injury |
| EP1708790B1 (en) * | 2003-12-02 | 2010-04-21 | PharmaNeuroBoost N.V. | Use of pipamperone and a d2-receptor antagonist or a serotonin/dopamin antagonist for the treatment of psychotic disorders |
| CN101516835A (zh) * | 2006-07-19 | 2009-08-26 | 俄亥俄州立大学研究基金会 | 选择性雄激素受体调节剂、它们的类似物和衍生物以及它们的用途 |
| HRP20100516T1 (hr) * | 2006-09-20 | 2010-10-31 | Eli Lilly And Company | Tiazolpirazolopirimidini kao antagonisti receptora crf1 |
| US20150094310A1 (en) * | 2012-04-23 | 2015-04-02 | Holsboermaschmeyer Neurochemie Gmbh | Crhr1 antagonists for use in the treatment of patients having crh overactivity |
| RS65839B1 (sr) * | 2014-01-21 | 2024-09-30 | Neurocrine Biosciences Inc | Crf1 receptor antagonisti za tretman kongenitalne adrenalne hiperplazije |
| JP7285222B2 (ja) * | 2017-08-14 | 2023-06-01 | スプルース バイオサイエンシズ インコーポレイテッド | 副腎皮質刺激ホルモン放出因子受容体拮抗薬 |
| WO2019036503A1 (en) * | 2017-08-14 | 2019-02-21 | Spruce Biosciences, Inc. | CORTICOTROPIN RELEASE FACTOR RECEPTOR ANTAGONISTS |
| EP4643950A3 (en) * | 2018-04-27 | 2026-01-14 | Spruce Biosciences, Inc. | Methods for treating testicular and ovarian adrenal rest tumors |
| US20220023266A1 (en) * | 2018-12-07 | 2022-01-27 | Neurocrine Biosciences, Inc. | Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia |
-
2020
- 2020-07-20 JP JP2022503463A patent/JP2022541550A/ja active Pending
- 2020-07-20 AU AU2020318970A patent/AU2020318970B2/en active Active
- 2020-07-20 WO PCT/US2020/042820 patent/WO2021016208A1/en not_active Ceased
- 2020-07-20 CN CN202080065892.7A patent/CN114423436A/zh active Pending
- 2020-07-20 BR BR112022000956A patent/BR112022000956A2/pt unknown
- 2020-07-20 TW TW109124484A patent/TW202116324A/zh unknown
- 2020-07-20 MX MX2022000812A patent/MX2022000812A/es unknown
- 2020-07-20 KR KR1020227005252A patent/KR20220052927A/ko active Pending
- 2020-07-20 CA CA3147891A patent/CA3147891A1/en active Pending
- 2020-07-20 EP EP20844541.1A patent/EP3986416A4/en active Pending
-
2022
- 2022-01-18 US US17/578,149 patent/US20220133742A1/en active Pending
-
2024
- 2024-02-09 US US18/438,060 patent/US20240261300A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20240261300A1 (en) | 2024-08-08 |
| CN114423436A (zh) | 2022-04-29 |
| AU2020318970A1 (en) | 2022-03-03 |
| EP3986416A4 (en) | 2023-06-28 |
| AU2020318970B2 (en) | 2026-04-16 |
| JP2022541550A (ja) | 2022-09-26 |
| TW202116324A (zh) | 2021-05-01 |
| US20220133742A1 (en) | 2022-05-05 |
| MX2022000812A (es) | 2022-02-16 |
| KR20220052927A (ko) | 2022-04-28 |
| EP3986416A1 (en) | 2022-04-27 |
| WO2021016208A1 (en) | 2021-01-28 |
| BR112022000956A2 (pt) | 2022-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2020318970B2 (en) | Methods of treating congenital adrenal hyperplasia | |
| AU2021324839B2 (en) | Methods and compositions for treating polycystic ovary syndrome | |
| JP7573080B2 (ja) | 副腎皮質刺激ホルモン放出因子受容体拮抗薬 | |
| US20200255436A1 (en) | Corticotropin releasing factor receptor antagonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20240719 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20240719 |
|
| P22 | Classification modified |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED Effective date: 20240812 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250113 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250113 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250113 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250611 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250612 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250612 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250612 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250627 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250627 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250711 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250711 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20251120 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20260312 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260317 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260317 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260317 |